EPT Disclosure

21 Jun 2006 10:20

GoldmanSachs International21 June 2006 FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION Name of exempt principal trader Goldman Sachs International Company dealt in CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC Class of relevant security to which the Ordinary Sharesdealings being disclosed relate (Note 1) Date of dealing 20 June 2006 2. DEALINGS (Note 2) (a) Purchases and sales Total number of securities purchased Highest price paid (Note 3) Lowest price paid (Note 3) 27200 13.09 GBP 13.09 GBP Total number of securities sold Highest price received (Note 3) Lowest price received (Note 3) 363235 13.11 GBP 13.09 GBP (b) Derivatives transactions (other than options) Product name, Long/short (Note 4) Number of securities (Note 5) Price per unit (Note 3)e.g. CFD CFD Long 50000 13.11 GBPCFD Long 300 13.11 GBPCFD Long 33605 13.11 GBPCFD Long 16182 13.11 GBPCFD Long 22403 13.11 GBPCFD Long 10788 13.11 GBPCFD Long 34500 13.11 GBPCFD Long 5500 13.11 GBPCFD Long 39000 13.11 GBPCFD Long 13500 13.11 GBPCFD Long 3000 13.11 GBPCFD Long 9109 13.11 GBPCFD Long 2950 13.11 GBPCFD Long 25863 13.11 GBPCFD Long 9088 13.11 GBPCFD Long 4450 13.11 GBPCFD Long 16766 13.11 GBPCFD Long 7401 13.11 GBPCFD Long 18500 13.11 GBPCFD Long 6500 13.11 GBPCFD Long 2130 13.11 GBPCFD Long 4500 13.11 GBP (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying Product name, Writing, selling, Number of securities to Exercise Type, e.g. Expiry Option money purchasing, which the option relates price American, date paid/received pere.g. call varying etc. (Note 5) European unit (Note 3)option etc. (ii) Exercising Product name, e.g. call option Number of securities Exercise price per unit (Note 3) 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the persondisclosing and any other person relating to the voting rights of any relevantsecurities under any option referred to on this form or relating to the votingrights or future acquisition or disposal of any relevant securities to which anyderivative referred to on this form is referenced. If none, this should bestated. Date of disclosure 21 June 2006 Contact name Peter Highton Telephone number +44-207-774-1935 Name of offeree/offeror with which connected Astrazeneca Nature of connection (Note 6) Advisor Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website atwww.thetakeoverpanel.org.uk This information is provided by RNS The company news service from the London Stock Exchange